UBS

UBS Group
D

UBS

Arincen57/100B

UBS Group income statement 1999–2026

76.36B USD over the last twelve months, and 73.84B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
76.36B73.84B74.22B57.38B36.82B35.03B32.07B35.47B36.85B35.78B36.91B
Revenue growth
+4.65%-0.51%+29.34%+55.83%+5.12%+9.21%-9.59%-3.73%+2.99%-3.08%+1.16%
Cost of revenue
24.10B27.07B33.13B25.02B6.09B2.84B4.36B7.13B115.16M129.17M38.86M
Gross profit
52.29B46.77B41.09B32.36B30.73B32.18B27.71B28.34B36.73B35.65B36.88B
Gross margin
68.49%63.34%55.36%56.39%83.45%91.88%86.39%79.90%99.69%99.64%99.89%
Selling, general and administrative
32.45B31.02B30.13B23.43B19.71B19.98B18.18B19.59B20.40B20.29B20.89B
Operating expenses
39.67B37.92B34.90B8.18B21.85B23.51B20.51B22.87B36.73B35.65B36.88B
12.62B8.85B6.19B24.17B8.88B8.67B7.20B5.47B5.95B0.000.00
Operating income growth
+55.76%+42.98%-74.38%+172.26%+2.41%+20.39%+31.65%-8.03%———
Operating margin
16.53%11.99%8.34%42.12%24.11%24.75%22.45%15.42%16.14%0.00%0.00%
Interest income
32.88B34.29B39.08B30.38B12.19B9.11B8.93B11.47B12.49B12.53B14.27B
Interest expense
23.64B26.55B32.63B24.14B6.07B2.98B3.75B7.05B———
Other non-operating income
—0.000.000.000.000.000.000.00-525.17M0.000.00
Pretax income
12.62B8.85B6.19B24.17B8.88B8.67B7.20B5.47B5.42B0.000.00
Income tax
2.92B1.06B1.52B746.80M1.80B1.83B1.40B1.24B1.46B0.000.00
Effective tax rate
23.18%11.93%24.56%3.09%20.22%21.07%19.41%22.72%26.88%——
9.65B7.77B4.62B23.41B7.05B6.82B5.79B4.22B4.48B0.000.00
Net income growth
+32.83%+68.23%-80.28%+231.95%+3.46%+17.73%+37.16%-5.85%———
Net margin
12.64%10.52%6.22%40.80%19.15%19.46%18.05%11.90%12.17%0.00%0.00%
Basic shares
3.32B3.18B3.35B3.30B3.39B3.62B3.71B3.77B3.84B3.84B3.80B
Diluted shares
3.43B3.31B3.35B3.30B3.40B3.63B3.71B3.77B3.84B3.84B3.82B
Change in diluted shares
+3.30%-1.33%+1.67%-2.99%-6.33%-2.15%-1.60%-1.94%+0.13%+0.33%+1.13%
EPS (basic)
2.992.461.598.302.342.141.771.141.170.250.90
EPS (diluted)
2.912.361.528.302.252.061.771.141.170.250.88
EPS growth
+30.49%+55.26%-81.69%+268.89%+9.22%+16.38%+55.26%-2.56%+368.00%-71.59%-46.99%
Dividends per share
1.100.900.700.550.500.370.730.690.650.600.88
Dividend growth
+22.22%+28.57%+26.79%+10.42%+35.14%-49.12%+5.74%+6.06%+7.85%-31.44%+10.29%
EBITDA
21.73B12.38B9.99B27.40B10.94B10.79B9.33B7.41B1.29B1.08B1.06B
EBITDA margin
28.46%16.77%13.46%47.74%29.71%30.80%29.08%20.89%3.51%3.01%2.88%
EBIT
18.63B8.85B6.19B24.17B8.88B8.67B7.20B5.47B0.000.000.00

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about UBS Group's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.